Stock price of Genzyme spiked on the news that FDA granted approval to Lumizymethel (aglucosidase alfa) for the treatment of late onset Pompe disease. Pompe disease is a rare and often fatal condition that disables the heart and muscles due to deficiency of ...
EXITING $GENZ WITH PROFIT AT $49.30
www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING
VERIFIABLE PERFORMANCE RECORD
Every closed trade since 2007, without exception, is included in the performance results.
Number of ...
CHECK OUR PERFORMANCE
